Busschots Katrien, De Rijck Jan, Christ Frauke, Debyser Zeger
Molecular Medicine, Molecular Virology and Gene Therapy, K.U.Leuven, Kapucijnenvoer 33, B-3000 Leuven, Belgium.
Mol Biosyst. 2009 Jan;5(1):21-31. doi: 10.1039/b810306b. Epub 2008 Oct 16.
One of the major obstacles to pursue the discovery of small molecule inhibitors targeting protein-protein interactions is the flat nature of their interface. X-Ray structures have indeed shown that a large part of the interaction area is buried with atoms closely packed together, implying a lack of available cavities for small molecule binding. Yet, it has become clear that some protein-protein interfaces have a well-defined compact area, commonly referred to as a hot spot, that plays a major role in the affinity of the interaction. These hot spots define potential targets for the development of small molecule protein-protein interaction inhibitors (SMPPIIs). In this review we discuss the interactions between viral and host proteins that have the potential for the future development of SMPPIIs. In light of the current anti-HIV therapy a short overview of protein-protein interactions that may serve as targets for novel drugs is provided. Our hypothesis will exemplify and discuss the interaction between HIV-1 integrase and its cellular cofactor LEDGF/p75, which, as evidenced by crystallography and site directed mutagenesis, displays favourable properties needed for the development of interaction inhibitors.
寻找靶向蛋白质-蛋白质相互作用的小分子抑制剂的主要障碍之一是其界面的扁平性质。X射线结构确实表明,大部分相互作用区域被紧密堆积在一起的原子所掩埋,这意味着缺乏可供小分子结合的空穴。然而,已经清楚的是,一些蛋白质-蛋白质界面有一个定义明确的紧密区域,通常称为热点,它在相互作用的亲和力中起主要作用。这些热点为小分子蛋白质-蛋白质相互作用抑制剂(SMPPIIs)的开发确定了潜在靶点。在这篇综述中,我们讨论了病毒蛋白与宿主蛋白之间的相互作用,这些相互作用具有未来开发SMPPIIs的潜力。鉴于当前的抗HIV疗法,我们简要概述了可能作为新型药物靶点的蛋白质-蛋白质相互作用。我们的假设将举例并讨论HIV-1整合酶与其细胞辅因子LEDGF/p75之间的相互作用,晶体学和定点诱变证明,这种相互作用具有开发相互作用抑制剂所需的有利特性。